BioArcticAB
@bioarcticab
Followers
302
Following
233
Media
43
Statuses
226
Biopharma. Neurodegenerative diseases. Corporate account publishing press releases for IR. GDPR info: https://t.co/1ZcLRn6LIh
Stockholm
Joined February 2021
PRESS RELEASE: Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology.
bioarctic.com
Stockholm, August 27, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical...
0
0
3
PRESS RELEASE: Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain.
bioarctic.com
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing...
0
0
1
PRESS RELEASE: Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates.
bioarctic.com
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has...
0
0
2
PRESS RELEASE: Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024.
bioarctic.com
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi[®] during the second quarter 2024, in...
0
0
4
PRESS RELEASE: Long-term treatment data for lecanemab to be presented at AAIC 2024
bioarctic.com
Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will present the latest findings on lecanemab (generic name, brand name Leqembi®) at...
0
0
4
PRESS RELEASE: Leqembi approved for the treatment of Alzheimer’s disease in Israel
bioarctic.com
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic name: lecanemab) has been approved for treatment of Alzheime...
0
0
3
PRESS RELEASE: Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong
bioarctic.com
Stockholm, Sweden, July 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Department of Health in Hong Kong has approved Leqembi® (brand name in Hong...
0
0
4
Press release: Leqembi[®] (lecanemab) launched in China https://t.co/qwmbjZXFV7
bioarctic.com
Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi[®] (brand name in China: “乐意保[®]”, generic name: lecanemab) has...
0
0
3
PRESS RELEASE: FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease.
bioarctic.com
Stockholm, Sweden, June 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Suppleme...
0
1
3
PRESS RELEASE: Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
bioarctic.com
Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea published that Leqembi® (lecanemab)...
0
1
6
PRESS RELEASE: Interim Report for the period January – March 2024
bioarctic.com
First BrainTransporter technology agreement signed Events during the first quarter 2024 Leqembi® was approved for the treatment of Alzheimer’s disease in China – launch planned for July 2024 The...
0
0
0
We’re pleased to share an update on the subcutaneous (SC) development program of our treatment for early #AlzheimersDisease (AD).
1
3
11
PRESS RELEASE: Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)
bioarctic.com
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for...
0
0
2
PRESS RELEASE: Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing.
bioarctic.com
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Application...
0
1
4
Press release: BioArctic and Eisai sign research evaluation agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidat.
0
4
12
Press release: BioArctic publishes the Annual Report for 2023
0
0
1
Press release: The Nomination Committee’s proposal for the election of Board members and Chairperson of the Board in BioArctic AB.
0
0
3
PRESS RELEASE: BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm.
0
0
1
PRESS RELEASE: Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed.
0
1
10
Press release: Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons.
0
0
1